Jaypirca(pirtobrutinib)
- Medicine Name: Jaypirca Tablets
- Generic Name: Pirtobrutinib
- Dosage form and Strengths: Tablets: 50 mg, 100 mg
- Manufactured by: Eli Lilly and Company
Indications and Usage
Jaypirca is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Dosage
Recommended Dosage: Take 200 mg orally once daily. Swallow the tablet whole with water, with or without food. Do not cut, crush, or chew the tablets.
Managing Toxicity: Toxicity can be managed through treatment interruption, dosage reduction, or discontinuation as needed.
Patients with Severe Renal Impairment: Reduce the dose in patients with severe renal impairment.
Contraindications: None.
- infections: Monitor for signs and symptoms of infection, evaluate promptly, and treat as necessary.
- Hemorrhage: Monitor for bleeding and manage appropriately.
- Cytopenias: Regularly monitor complete blood counts during treatment.
- Atrial Fibrillation and Atrial Flutter: Be vigilant for symptoms of arrhythmias and manage appropriately.
- Second Primary Malignancies: Other malignancies, including skin cancers and other carcinomas, have been reported. Monitor patients and advise sun protection.
- Embryo-Fetal Toxicity: Jaypirca can cause fetal harm. Females of reproductive potential should be informed of the potential risk to a fetus and use effective contraception.
- Strong CYP3A Inhibitors: Avoid concomitant use. If unavoidable, reduce the Jaypirca dose.
- Strong or Moderate CYP3A Inducers: Avoid concomitant use. If moderate CYP3A inducers’ concomitant use is unavoidable, increase the Jaypirca dose.
- Sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP Substrates: Follow recommendations for co-administration with CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP inhibitors provided in their approved product labeling when minimal concentration changes may increase the risk of adverse reactions.
- Consult with Your Healthcare Provider
- Locate a Pharmacy or Distributor
- Provide Your Prescription
- Insurance and Coverage Check
- Place Your Order
- Review Medication Instructions
- Follow Up with Your Healthcare Provider
- Refill as Needed
What documents are required to import Jaypirca to India?
Jaypirca (pirtobrutinib) Tablets can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients ID Proof (issued by the government of India)
How does the order be confirmed?
- The order will be confirmed only after the receipt of:
- A valid prescription from Doctor
- Import permit if applicable
Is Jaypirca(pirtobrutinib) available in India?
Jaypirca (pirtobrutinib) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input
- On availability of Jaypirca in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
- Medicine Price.
- Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
- Ensuring 100% transparency.
Jaypirca (pirtobrutinib) can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.
IPN (Indian Pharma Network) can facilitate the supply of Jaypirca (pirtobrutinib) (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Jaypirca Tablets price in India.
We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.
Indian Pharma Network is able to source the Jaypirca (pirtobrutinib) (Cancer Treatment Medicines) from across the globe and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is Jaypirca ?
Jaypirca is a medication used for the treatment of mantle cell lymphoma (MCL) in adult patients who have relapsed or refractory MCL after at least two lines of systemic therapy, including a BTK inhibitor.
How do I take Jaypirca ?
Jaypirca is taken orally once daily with water. It should be swallowed whole and can be taken with or without food. Do not cut, crush, or chew the tablets.
Is a prescription required for Jaypirca ?
Yes, a prescription from a healthcare provider is required to obtain Jaypirca . Your healthcare provider will assess your eligibility and prescribe the appropriate dosage.
Are there any common side effects of Jaypirca ?
Common side effects of Jaypirca may include fatigue, musculoskeletal pain, diarrhea, edema, dyspnea, pneumonia, and bruising. Discuss any side effects with your healthcare provider.
Can I order Jaypirca online?
Ordering Jaypirca typically requires coordination with a healthcare provider and a pharmacy or distributor. You’ll need a prescription to place an order. We at Indian Pharma Network can provide you Jaypirca online.
Is Jaypirca FDA approved?
Yes, it got approved in 2023 for use.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.